Cancer has proven to be one of the most difficult diseases to fight. We spend billions a year trying to cure it, but there are few successful breakthroughs or notable discoveries. This is all changing thanks to the likes of Clay Siegall and his work at Seattle Genetics. He has taken his decades of research and used it to create some of the most successful drug innovations out there. Particularly, his antibody-drug conjugate has been enormously successful and provided patients with a new way to fight cancer. If he continues to succeed we may see an entirely new way of fighting disease.
Decades Of Important Research
Throughout the late 80s and 90s Siegall spent his time working for research institutes with an eye on the possibility of finding a cure for cancer. His research gave him an insight into how cancer grows and how to inhibit that growth in the body, but more importantly it made him familiar with the struggles of cancer patients. He now uses that understanding to develop tools that will help cancer patients better survive the treatments they must undergo.
Breakthroughs Lead To Innovation
When he decided to found Seattle Genetics in the early 2000s, Siegall had decided he was going to find a way to turn his knowledge into an actual drug. His antibody-drug conjugate gave patients a level of care they didn’t have before. Now, patients are finally able to live without the side effects often found in chemotherapy patients. Seattle Genetics has even attracted the attention of many major investors for its ability to produce some of the most successful innovations around. There continues to be great interest in the future of this company.
The Future Is Bright
Seattle Genetics is always on the rise and it has proven to be one of the most prominent biotech companies of our time. As the future continues to favor companies such as this we can only begin to speculate at the influence of Clay Siegall. He’s certainly left an impact we can see, but there is a path to do even more.